Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBK019
- Development stage
- Preclinical
- Lead developer
- Chengdu Shibeikang Biomedical Technology
- Modality
- Small Molecules
01
Overview
SBK019 is a preclinical-stage small molecule drug candidate developed by Chengdu Shibeikang Biotechnology for the treatment of cardiovascular and cerebrovascular diseases. The asset is described as employing a multi-target engagement strategy with synergistic mechanisms, a design philosophy shared with other assets in the company's cardiovascular portfolio (such as SBK002 and SBK008). While the specific molecular targets have not been publicly disclosed, the drug is intended to address complex disease pathways through polypharmacology. It is currently in the scientific R&D phase and has not yet entered formal clinical trials.
Beyond the preview
Go deeper on SBK019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBK019.